US EditionDenmark Compensates Four over Vision Loss Linked to Ozempic, Wegovy
Denmark's independent body ruled four patients eligible for compensation after vision loss linked to semaglutide drugs, which affect 1 in 10,000 users, the Pharmacovigilance Risk Assessment Committee said.
- On Friday at The Hindu's Lit for Life Dialogue 2025, panelists at the Museum of Art and Photography, Bengaluru said Ozempic should be taken under doctor’s advice and used to support weight loss, not as a quick fix.
- Experts noted that the drug alters appetite hormones, so Ozempic curbs cravings by changing hormones controlling appetite and satiety, fitting obesity's medical definition due to related health issues.
- The endocrinologist said the minimum weaning should be at least two years, warning unregulated short-term use could have long-term repercussions and recommending dosage tapering with diet and exercise.
- On November 21, 2025, a Danish panel ruled that four people who developed NAION after using Wegovy and Ozempic merit 800,000 kroner compensation, the Danish Patient Compensation association said.
- Following PRAC's findings, Novo Nordisk updated patient leaflets to include NAION as a "very rare" side effect affecting up to 1 in 10,000 users, after a 2024 review request by the Danish Medicines Agency.
27 Articles
27 Articles
Medicines such as Wegovy and Ozempic are very popular in the fight against obesity. However, they have a rare but severe side effect: a marked visual deterioration. In Denmark, dozens of people suffer from the disease demand compensation. Four of them receive compensation - further applications are still ongoing.
In Denmark, at least four patients suffered severe visual damage after taking weight loss medications. It was the weight loss medication Wegovy as well as the diabetes medicine Ozempic. Together, the patients now receive compensation payments worth around 107,000 euros from the state. Patients developed the eye disease NAION (non-arteritic anterior ischaemic optic neuropathy), which results in a strong and mostly permanent visual deterioration.
The Danish state pays over 100,000 euros to four people who have developed an eye disease through the medicines Wegovy and Ozempic. Dozens of other cases still have to be investigated.
Coverage Details
Bias Distribution
- 60% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
